Literature DB >> 1368228

High level Escherichia coli expression and production of a bivalent humanized antibody fragment.

P Carter1, R F Kelley, M L Rodrigues, B Snedecor, M Covarrubias, M D Velligan, W L Wong, A M Rowland, C E Kotts, M E Carver.   

Abstract

Many clinical uses of antibodies will require large quantities of fragments which are bivalent and humanized. We therefore attempted to generate humanized F(ab')2 fragments by secretion from E. coli. Titers of 1-2 g l-1 of soluble and functional Fab' fragments have been routinely achieved as judged by antigen-binding ELISA. Surprisingly, this high expression level of Fab' in the periplasmic space of E. coli does not drive dimerization. However, we have developed a protocol to directly and efficiently recover Fab' with the single hinge cysteine in the free thiol state, allowing F(ab')2 formation by chemically-directed coupling in vitro. The E. coli derived humanized F(ab')2 fragment is indistinguishable from F(ab')2 derived from limited proteolysis of intact antibody in its binding affinity for the antigen, p185HER2, and anti-proliferative activity against the human breast tumor cell line, SK-BR-3, which over-expresses p185HER2. This system makes E. coli expression of bivalent antibody fragments for human therapy (or other uses) practical.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1368228     DOI: 10.1038/nbt0292-163

Source DB:  PubMed          Journal:  Biotechnology (N Y)        ISSN: 0733-222X


  38 in total

1.  Longitudinal epitope analysis of insulin-binding antibodies in type 1 diabetes.

Authors:  T R Hall; J W Thomas; C J Padoa; C Torn; M Landin-Olsson; E Ortqvist; C S Hampe
Journal:  Clin Exp Immunol       Date:  2006-10       Impact factor: 4.330

Review 2.  Review: optimizing inducer and culture conditions for expression of foreign proteins under the control of the lac promoter.

Authors:  R S Donovan; C W Robinson; B R Glick
Journal:  J Ind Microbiol       Date:  1996-03

3.  APEx 2-hybrid, a quantitative protein-protein interaction assay for antibody discovery and engineering.

Authors:  Ki Jun Jeong; Min Jeong Seo; Brent L Iverson; George Georgiou
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-09       Impact factor: 11.205

4.  Selective and efficient extraction of recombinant proteins from the periplasm of Escherichia coli using low concentrations of chemicals.

Authors:  Reza Jalalirad
Journal:  J Ind Microbiol Biotechnol       Date:  2013-07-18       Impact factor: 3.346

5.  Clonal relationships between thyroid-stimulating hormone receptor-stimulating antibodies illustrate the effect of hypermutation on antibody function.

Authors:  Carolyn J Padoa; Sanne L Larsen; Christiane S Hampe; Jacqueline A Gilbert; Elif Dagdan; Laszlo Hegedus; Deborah Dunn-Walters; J Paul Banga
Journal:  Immunology       Date:  2009-10-21       Impact factor: 7.397

6.  Potent anti-CD5 ricin A chain immunoconjugates from bacterially produced Fab' and F(ab')2.

Authors:  M Better; S L Bernhard; S P Lei; D M Fishwild; J A Lane; S F Carroll; A H Horwitz
Journal:  Proc Natl Acad Sci U S A       Date:  1993-01-15       Impact factor: 11.205

7.  A phage display approach for rapid antibody humanization: designed combinatorial V gene libraries.

Authors:  C Rader; D A Cheresh; C F Barbas
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-21       Impact factor: 11.205

8.  Phage display of a catalytic antibody to optimize affinity for transition-state analog binding.

Authors:  M Baca; T S Scanlan; R C Stephenson; J A Wells
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-16       Impact factor: 11.205

9.  Remodeling domain interfaces to enhance heterodimer formation.

Authors:  Z Zhu; L G Presta; G Zapata; P Carter
Journal:  Protein Sci       Date:  1997-04       Impact factor: 6.725

10.  Development of anti-p185HER2 immunoliposomes for cancer therapy.

Authors:  J W Park; K Hong; P Carter; H Asgari; L Y Guo; G A Keller; C Wirth; R Shalaby; C Kotts; W I Wood
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.